Senior Medical Science Liaison, Rare Disease (Neuromuscular):
REGENXBIO

1566910720
REGENXBIO
Rockville Maryland
Biotech
Apply
Description
Who we are:

REGENXBIO is an exceptional place to work. You'll have the opportunity to collaborate with some of the best and the brightest people, touch amazing science, and be a part of extraordinary plans. Our core values: Trust, Accountability, Perseverance, and Innovation drive everything we do. We aim to bring these values to life every day with all that we do, and we believe that what we do matters - to patients, to their families, and to their communities.

The opportunity:

The Senior Medical Science Liaison, Rare Diseases is a field based scientific expert that provides field medical support for REGENXBIO Rare Disease pre-commercial clinical trials and scientific collaborations. This is an exciting opportunity for an innovative MSL with an entrepreneurial spirit who enjoys building networks, managing KOL advisors, conducting scientific exchanges, planning, and executing advisory boards, and supporting company sponsored research. This is a contract to perm position (9 months).

What you'll be doing:

* Serve as the field-based Medical Affairs representative to establish and cultivate scientific relationships with external stakeholders in the rare disease community.
* Develop a strong understanding of clinical practice as it relates to areas of interest for REGENXBIO and identify, gather, and document field generated scientific insights to inform executable and innovative Medical Affairs strategies.
* Assist with clinical trial recruitment and site outreach as requested and communicate feedback to the Clinical Operations and Clinical Development team.
* Participate in KOL mapping and the development of a customer-centric tactical engagement plan to support Medical Affair's strategies.
* Serve as a resource for addressing unsolicited medical questions about REGENXBIO's trials, products, and other scientific exchange matters.
* Provide clinical expertise in the development, management, and maintenance of clinical and scientific communications, including publications, slide decks, educational materials, meeting presentations and FAQs.
* Attend medical conferences as MA representative and assist with congress strategy/ planning, medical booth staffing, competitive intelligence/ insights gathering, and generating meeting summaries.
* Maintain scientific and clinical knowledge base in the relevant therapeutic areas through continuous learning and awareness of related scientific literature to enable meaningful scientific exchange.
* Collaborate with internal colleagues to provide scientific expertise and share medical insights in support of internal and external activities.
* Assistance with planning and executing advisory board meetings.
* Expected to make important contributions to the MA strategy across therapeutic areas.

What we're looking for:

We set our employees up for success. To be successful in this role and help us achieve our goals, we are looking for someone with the following skills and qualifications:

* Master's degree (MPH or equivalent) required. Doctorate level (MD, PharmD, PhD) preferred.
* Minimum of 3 years of rare disease clinical or therapeutic experience in neuromuscular diseases, and/ or gene therapy strongly preferred.
* 3-5 years of MSL experience in rare disease state with primary emphasis on field based scientific exchange and/or clinical trial support.
* Superior communication, relationship building and interpersonal skills.
* Ability to assimilate new clinical data quickly.
* Proactive problem-solving skills.
* Project management and medical writing skills.
* Flexibility, resilience, and creativity/ innovation in their work
* Ability to organize and lead high level projects.
* Ability to proactively predict issues and solve problems.
* Ability to work collaboratively with cross-functional teams.

Why should you apply?

By joining REGENXBIO, you will have the opportunity to be a part of a growing company, with an incredible team, who is passionate about developing novel AAV gene therapies for patients in need.